Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
NASDAQ:SGMO
Holding SGMO?
Track your performance easily
SGMO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.30 - $3.18
Previous Close$1.9
Volume6.36M
Average Volume (3M)7.21M
Market Cap
$427.73M
Enterprise Value$416.25M
Total Cash (Recent Filing)$39.20M
Total Debt (Recent Filing)$27.73M
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Feb 19, 2025EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding208,646,870
10 Day Avg. Volume10,423,265
30 Day Avg. Volume7,208,630
Standard Deviation0.35
R-Squared0.03
Alpha0.00252
Financial Highlights & Ratios
Price to Book (P/B)10.79
Price to Sales (P/S)8.18
Price to Cash Flow (P/CF)9.10
P/FCF Ratio9.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.96
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$6.00Price Target Upside206.12% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Sangamo Biosciences News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAll 18 patients remain off enzyme replacement therapy, indicating success in treatment.
Partnership OpportunitiesThe highly favorable regulatory path offered by FDA for Fabry is expected to greatly facilitate partnership formation, which is important to extend cash runway.
Regulatory DevelopmentsThe FDA has granted Orphan Drug, Fast Track, and regenerative medicine advanced therapy designations for isa-vec in Fabry disease.
Bears Say
Clinical DevelopmentRisks include clinical development risk tied to giro-vec and isa-vec, commercialization risk, reimbursement risk, capital markets and dilution risk, pricing risk, business development risk, and clinical trial risk related to the war in Eastern Europe.
EarningsNet loss per share was ($0.18) vs. consensus of ($0.15).
Financial PerformanceSGMO reported 4Q23 net loss of ~$60M.
---
Ownership Overview
2.95% Insiders
17.79% Mutual Funds
10.50% Other Institutional Investors
63.30% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMO FAQ
What was Sangamo Biosciences’s price range in the past 12 months?
Sangamo Biosciences lowest stock price was $0.30 and its highest was $3.18 in the past 12 months.
What is Sangamo Biosciences’s market cap?
Currently, no data Available
When is Sangamo Biosciences’s upcoming earnings report date?
Sangamo Biosciences’s upcoming earnings report date is Feb 19, 2025 which is in 90 days.
How were Sangamo Biosciences’s earnings last quarter?
Sangamo Biosciences released its earnings results on Nov 12, 2024. The company reported $0.04 earnings per share for the quarter, beating the consensus estimate of -$0.015 by $0.055.
Is Sangamo Biosciences overvalued?
According to Wall Street analysts Sangamo Biosciences’s price is currently Undervalued.
Does Sangamo Biosciences pay dividends?
Sangamo Biosciences does not currently pay dividends.
What is Sangamo Biosciences’s EPS estimate?
Sangamo Biosciences’s EPS estimate is -$0.09.
How many shares outstanding does Sangamo Biosciences have?
Sangamo Biosciences has 208,646,870 shares outstanding.
What happened to Sangamo Biosciences’s price movement after its last earnings report?
Sangamo Biosciences reported an EPS of $0.04 in its last earnings report, beating expectations of -$0.015. Following the earnings report the stock price went down -9.963%.
Which hedge fund is a major shareholder of Sangamo Biosciences?
Among the largest hedge funds holding Sangamo Biosciences’s share is Wexford Capital LP. It holds Sangamo Biosciences’s shares valued at N/A.
---
Sangamo Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (206.12% Upside)
$6.00 (206.12% Upside)
Blogger Sentiment
Bullish
SGMO Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 45.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.3%
Last 30 Days ▲ 20.7%
Last 30 Days ▲ 20.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
394.79%
12-Months-Change
Fundamentals
Return on Equity
-156.42%
Trailing 12-Months
Asset Growth
-49.36%
Trailing 12-Months
Company Description
Sangamo Biosciences
Sangamo Therapeutics, Inc. engages in researching and developing transcription factors in the regulation of genes. It focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins. The company was founded by Edward O. Lanphier II in 1995 and is headquartered in Richmond, CA.
---
SGMO Company Deck
---
SGMO Earnings Call
Q3 2024
0:00 / 0:00
---
SGMO Stock 12 Month Forecast
Average Price Target
$6.00
▲(206.12% Upside)
Technical Analysis
Best Analysts Covering SGMO
1 Year
1 Year Success Rate
9/16 ratings generated profit
1 Year Average Return
+93.12%
assigned a buy rating 7 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 56.25% of your transactions generating a profit, with an average return of +93.12% per trade.
---